Abstract
Introduction: The best treatment for relapsed platinum sensitive epithelial ovarian cancer (EOC) is controversial. The aim of the study was to compare progression-free survival (PFS) and overall survival (OS) in platinum-sensitive EOC patients treated with chemotherapy alone (CTA), secondary cytoreductive surgery (SCR) or SCR plus hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC). Materials and Methods: Retrospective analysis of the clinical outcome of 46 EOC patients with at least 30 months of follow-up. Results: Median follow-up time was 32 months for the CTA group, 30 months for the SCR group, and 45 months for the SCR + HIPEC group. Fifteen recurrences were observed in the CTA group, seven in the SCR group, and 16 in the SCR + HIPEC group. The median time elapsed between first and second recurrence (PFI-2) was significantly higher among patients treated with SCR + HIPEC, in comparison with patients treated with CTA (p = 0.012 and p = 0.017, respectively). On the contrary, PFI-2 did not significantly differ between the SCR and SCR + HIPEC groups (p = 0.877). A statistically significant difference in OS favouring SCR + HIPEC in comparison with CTA (p = 0.04) was observed. Conclusions: SCR ± HIPEC compared with CTA improves PFI-2 in patients with platinum-sensitive EOC recurrence. SCR + HIPEC might also improve OS in comparison with CTA. No improvement in favor of SCR + HIPEC vs SCR was observed,. These results further support the need of a randomized trial comparing chemotherapy with SCR ± HIPEC in this setting.
| Original language | English |
|---|---|
| Pages (from-to) | 638-643 |
| Number of pages | 6 |
| Journal | European Journal of Gynaecological Oncology |
| Volume | 37 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
Keywords
- Cytoreductive surgery
- HIPEC
- Ovarian cancer
- Platinum based chemotherapy
- Platinum sensitive relapse
- Secondary cytoreduction
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynaecology
Cite this
Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone : A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer. / Marocco, F.; Vaira, M.; Milani, A.; Genta, S.; Maggiorotto, F.; Magistris, A.; Cinquegrana, A.; Robella, M.; De Simone, M.; Aglietta, M.; Ponzone, R.; Valabrega, G.
In: European Journal of Gynaecological Oncology, Vol. 37, No. 5, 2016, p. 638-643.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone
T2 - A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer
AU - Marocco, F.
AU - Vaira, M.
AU - Milani, A.
AU - Genta, S.
AU - Maggiorotto, F.
AU - Magistris, A.
AU - Cinquegrana, A.
AU - Robella, M.
AU - De Simone, M.
AU - Aglietta, M.
AU - Ponzone, R.
AU - Valabrega, G.
PY - 2016
Y1 - 2016
N2 - Introduction: The best treatment for relapsed platinum sensitive epithelial ovarian cancer (EOC) is controversial. The aim of the study was to compare progression-free survival (PFS) and overall survival (OS) in platinum-sensitive EOC patients treated with chemotherapy alone (CTA), secondary cytoreductive surgery (SCR) or SCR plus hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC). Materials and Methods: Retrospective analysis of the clinical outcome of 46 EOC patients with at least 30 months of follow-up. Results: Median follow-up time was 32 months for the CTA group, 30 months for the SCR group, and 45 months for the SCR + HIPEC group. Fifteen recurrences were observed in the CTA group, seven in the SCR group, and 16 in the SCR + HIPEC group. The median time elapsed between first and second recurrence (PFI-2) was significantly higher among patients treated with SCR + HIPEC, in comparison with patients treated with CTA (p = 0.012 and p = 0.017, respectively). On the contrary, PFI-2 did not significantly differ between the SCR and SCR + HIPEC groups (p = 0.877). A statistically significant difference in OS favouring SCR + HIPEC in comparison with CTA (p = 0.04) was observed. Conclusions: SCR ± HIPEC compared with CTA improves PFI-2 in patients with platinum-sensitive EOC recurrence. SCR + HIPEC might also improve OS in comparison with CTA. No improvement in favor of SCR + HIPEC vs SCR was observed,. These results further support the need of a randomized trial comparing chemotherapy with SCR ± HIPEC in this setting.
AB - Introduction: The best treatment for relapsed platinum sensitive epithelial ovarian cancer (EOC) is controversial. The aim of the study was to compare progression-free survival (PFS) and overall survival (OS) in platinum-sensitive EOC patients treated with chemotherapy alone (CTA), secondary cytoreductive surgery (SCR) or SCR plus hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC). Materials and Methods: Retrospective analysis of the clinical outcome of 46 EOC patients with at least 30 months of follow-up. Results: Median follow-up time was 32 months for the CTA group, 30 months for the SCR group, and 45 months for the SCR + HIPEC group. Fifteen recurrences were observed in the CTA group, seven in the SCR group, and 16 in the SCR + HIPEC group. The median time elapsed between first and second recurrence (PFI-2) was significantly higher among patients treated with SCR + HIPEC, in comparison with patients treated with CTA (p = 0.012 and p = 0.017, respectively). On the contrary, PFI-2 did not significantly differ between the SCR and SCR + HIPEC groups (p = 0.877). A statistically significant difference in OS favouring SCR + HIPEC in comparison with CTA (p = 0.04) was observed. Conclusions: SCR ± HIPEC compared with CTA improves PFI-2 in patients with platinum-sensitive EOC recurrence. SCR + HIPEC might also improve OS in comparison with CTA. No improvement in favor of SCR + HIPEC vs SCR was observed,. These results further support the need of a randomized trial comparing chemotherapy with SCR ± HIPEC in this setting.
KW - Cytoreductive surgery
KW - HIPEC
KW - Ovarian cancer
KW - Platinum based chemotherapy
KW - Platinum sensitive relapse
KW - Secondary cytoreduction
UR - http://www.scopus.com/inward/record.url?scp=84994434531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994434531&partnerID=8YFLogxK
U2 - 10.12892/ejgo3257.2016
DO - 10.12892/ejgo3257.2016
M3 - Article
AN - SCOPUS:84994434531
VL - 37
SP - 638
EP - 643
JO - European Journal of Gynaecological Oncology
JF - European Journal of Gynaecological Oncology
SN - 0392-2936
IS - 5
ER -